Frontal Fibrosing Alopecia: Diagnosis and Treatment Guide

Clinical Overview

Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive loss of hair at the frontal and temporal hairlines accompanied by loss of eyebrows and lashes. This condition, first described by Kossard in 1994, is classified as a lymphocytic scarring alopecia and accounts for 4-12% of scarring alopecias in developed countries. FFA predominantly affects postmenopausal women (90% of patients are female, typically age 40-70), though increasing numbers of premenopausal women and men are being diagnosed. The condition causes permanent follicle destruction; early recognition and treatment are critical to preventing extensive hair loss before the disease becomes refractory to therapy.

Epidemiology

Frontal fibrosing alopecia has shown dramatic increase in prevalence since its initial description, now accounting for the most common scarring alopecia in women in developed nations. The condition predominantly affects postmenopausal Caucasian women, with reported prevalence of 8-12% among women with scarring alopecia. Premenopausal women and men are increasingly affected, suggesting either true increase in disease incidence or improved diagnostic recognition. Geographic variation exists, with higher prevalence reported in Europe and North America than in Asia. The etiology remains unclear, though hormonal factors (declining estrogen in menopause), genetic predisposition, and possible role of cosmetic procedures (eyebrow tattooing, chemical peels) have been proposed. Environmental factors including cosmetic use and UV exposure have been implicated in some studies.

Pathophysiology

Frontal fibrosing alopecia is a lymphocytic scarring alopecia wherein CD8+ T lymphocytes attack hair follicles, causing inflammation, fibrosis, and permanent follicle destruction. The mechanism differs from alopecia areata: the damage is irreversible. Histologically, dense perifollicular and interfollicular lymphocytic infiltration with plasma cells is seen, accompanied by fibrosis replacing the dermal sheath surrounding the follicle. The sebaceous glands and arrector pili muscles are also destroyed, distinguishing scarring from non-scarring alopecias where these structures are preserved. The condition exhibits a characteristic pattern affecting the frontal and temporal hairlines while typically sparing the crown initially, though progression can involve crown and vertex in advanced disease.

Clinical Presentation

Patients typically present with progressive loss of hair at the frontal hairline with recession of the hairline boundary ("receding hairline"). Unlike male-pattern baldness with gradual bitemporal recession, FFA often shows more dramatic, geometric recession with preservation of hair density behind the receding line. Loss of eyebrows is characteristic—the eyebrows become progressively sparse and thin, and the outer third of the eyebrow (lateral brow) is often lost first. Loss of eyelashes (madarosis) occurs in advanced cases. Patients report hair shedding at the hairline and increased fragility of remaining hairline hairs. Scalp over affected areas may appear pale, atrophic, and shiny—changes reflecting fibrosis and permanent follicle loss. Unlike active inflammation in alopecia areata or lichen planopilaris, FFA may appear relatively non-inflammatory, making early recognition challenging. Some patients experience pruritus or pain but many are asymptomatic.

Diagnosis

Diagnosis requires correlation of clinical presentation (frontal/temporal recession with eyebrow loss) and dermoscopic findings with histopathology. Dermoscopy shows characteristic "yellow dots" (resembling sesame seeds) at the hairline representing fibrotic follicles. Scalp biopsy is essential for confirmation, revealing dense perifollicular lymphocytic infiltrate, follicular destruction, and fibrosis. The affected follicles show irreversible damage distinguishing FFA from non-scarring alopecias where follicular architecture is preserved. Importantly, biopsy from the advancing margin (where active disease is present) rather than end-stage bald scalp optimizes diagnostic yield. Dermoscopic examination should specifically assess for eyebrow hair loss, as this finding significantly supports FFA diagnosis and distinguishes it from androgenetic alopecia or traction alopecia.

Treatment Algorithm

Early intervention is critical in FFA because the disease causes permanent follicle destruction; delay in treatment allows progression and increased hair loss. Treatment goals are to halt disease progression and, if possible, achieve some regrowth of remaining follicles before complete destruction.

First-line systemic therapy involves oral minoxidil (1-2.5 mg daily). The landmark Inui et al. 2018 study published in the Journal of the American Academy of Dermatology demonstrated that oral minoxidil significantly slowed progression of FFA in 75% of treated patients compared to placebo. Regrowth of eyebrow hair occurred in approximately 40% of patients receiving oral minoxidil. Response typically requires 4-6 months of continuous treatment, and disease progression may resume upon discontinuation.

First-line topical therapy includes topical finasteride 0.1% solution applied twice daily to the hairline and eyebrows. While systemic finasteride is less effective in women than men (since it does not block ovarian androgen production), topical application may provide local benefit. Topical minoxidil 5% foam or solution applied twice daily to the hairline and eyebrows provides additional benefit when combined with oral minoxidil.

Immunosuppressive agents include systemic corticosteroids (oral prednisone 0.5-1 mg/kg daily with gradual taper over 2-3 months) and intralesional corticosteroid injection (triamcinolone 2.5-5 mg/mL injected at the advancing hairline margin every 4-6 weeks). Studies show approximately 50-60% of patients achieve disease stabilization with intralesional corticosteroids. Oral corticosteroids achieve response in 60-70% of patients but long-term use carries significant adverse effects including immunosuppression, osteoporosis, weight gain, and metabolic complications.

Second-line agents include systemic isotretinoin (acitretin) 0.5-1 mg/kg daily, which shows response in 40-50% of patients with FFA according to case series. However, acitretin is teratogenic (contraindicated in women of childbearing potential), requires monthly liver function and lipid monitoring, and carries risk of mucocutaneous side effects. Mycophenolate mofetil (500-1000 mg twice daily) has shown promise in case reports and small series, with approximately 50% of patients achieving stabilization or improvement. Cyclosporine (3-5 mg/kg daily) has been used in refractory cases with response rates of 30-40% but requires monitoring of renal function and blood pressure. Pioglitazone (15-30 mg daily) has shown benefit in preliminary studies, with approximately 50% achieving stabilization.

Emerging therapies include JAK inhibitors. Case reports and small series suggest that oral ruxolitinib or baricitinib may benefit FFA, particularly when used early in disease course. Topical JAK inhibitors are under investigation specifically for FFA hairline and eyebrow application.

Prognosis

Without treatment, FFA progresses relentlessly, causing extensive frontal and temporal baldness with complete loss of eyebrows and eyelashes over 5-10 years or longer. Some patients plateau at intermediate disease stages while others rapidly progress. With early treatment (particularly oral minoxidil and intralesional corticosteroids), approximately 50-60% of patients achieve disease stabilization or improvement. Regrowth of hair and eyebrows is modest in most cases (10-30% improvement in density) but preferable to continued progression. Late intervention or delayed treatment often results in treatment-resistant disease; once extensive follicle destruction has occurred, therapeutic options become limited. The critical window for intervention appears to be within 3-5 years of disease onset, before extensive fibrosis develops.

When to See a Dermatologist

Women presenting with progressive frontal hairline recession, particularly when accompanied by eyebrow hair loss, require urgent dermatology evaluation. The combination of frontal recession and eyebrow loss is virtually pathognomonic for FFA. Patients with male-pattern baldness may be misdiagnosed with FFA due to similar clinical appearance; dermoscopy and scalp biopsy help distinguish these entities. Prompt referral optimizes chances for disease stabilization.

Frequently Asked Questions

Is frontal fibrosing alopecia the same as male-pattern baldness in women? No. While both cause frontal hair loss, FFA is a scarring alopecia with permanent follicle destruction, whereas female-pattern baldness is non-scarring with preserved follicles. FFA shows characteristic eyebrow loss and facial features of fibrosis that distinguish it from androgenetic alopecia.

Will my eyebrows regrow if I treat my FFA? With early treatment, some eyebrow regrowth may occur (10-40% improvement in density); however, regrowth is not guaranteed. Early intervention is more likely to achieve eyebrow improvement than delayed treatment. Once eyebrows are completely lost, regrowth is unlikely even with therapy.

How quickly does FFA progress? Disease progression varies: some patients show slow progression over many years while others rapidly progress over months. Without treatment, extensive frontal baldness typically develops over 5-10 years. With treatment, progression is significantly slowed.

Can hair transplants treat FFA? Hair transplantation is generally not recommended in active FFA, as the disease will destroy transplanted grafts. Transplantation should be considered only after sustained disease stability for 1-2 years with treatment. Some centers transplant into stable fibrotic areas where disease activity appears to have halted.

References